<DOC>
	<DOCNO>NCT01091116</DOCNO>
	<brief_summary>The purpose study determine whether intra-articular ( knee joint ) administration MEN16132 effective reduce pain knee osteoarthritis .</brief_summary>
	<brief_title>A Locally Injected Bradykinin Antagonist TReatment OSteoarthritiS</brief_title>
	<detailed_description>MEN16132 non-peptide bradykinin B2-receptor antagonist show analgesic anti-inflammatory activity nonclinical osteoarthritis model . This study conduct dose finding study determine safety efficacy MEN16132 , give three doses/four treatment regimen comparison placebo , well time onset duration effect .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>( 4-amino-5- ( 4- ( 4- ( 2,4-dichloro-3- ( 2,4-dimethyl-8-quinolyloxymethyl ) phenylsulfonamido ) tetrahydro-2H-4-pyranoylcarbonyl ) piperazino ) -5-oxopentyl ) ( trimethyl ) ammonium</mesh_term>
	<criteria>Main Male female patient ≥40 year old . Symptomatic primary knee osteoarthritis ( ACR criterion ) since ≥6 month prior screen , Kellgren Lawrence Grade 2 3 , represent indication intraarticular drug injection . &gt; 50 mm VAS pain score assign index knee WOMAC VA 3.1A1 ( pain walk flat surface ) . &gt; 125 mm VAS pain score assign index knee WOMAC VA 3.1 A subscore ( total pain ) . Pain index knee least 50 % day month precede screen . Main Patients Kellgren &amp; Lawrence Grade I IV ( doubtful severe ) osteoarthritis knee . Knee condition represent indication surgery Patients Inflammatory crystal arthropathy , acute fracture , severe loss bone density , bone necrosis . Patients isolated patellafemoral syndrome chondromalacia . Patients OA predominant lateral compartment significant valgus deformity . Patients disease condition interfere free use evaluation index knee 3 month duration trial ( e.g . cancer , congenital defect , spine osteoarthritis ) . Major injury surgery index knee within previous 12 month prior screen . Severe hip osteoarthritis ipsilateral index knee . Any pain &gt; 30 mm VAS could interfere assessment index knee pain ( e.g . pain part low extremity , pain radiate knee ) . Any pharmacological nonpharmacological treatment start change 4 week prior randomisation likely change duration study Use systemic topical corticosteroid &gt; 10 mg prednisolone equivalent per day 30 day prior randomisation . Use pain OA medication ( e.g . NSAIDs , COX2 inhibitor , analgesic ) 1 2 week prior randomisation . Any intraarticular local periarticular punction , injection surgery index knee 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Injections , Intra-Articular</keyword>
</DOC>